Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN

AMGEN INC.

(AMGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2020 09/21/2020 09/22/2020 09/23/2020 09/24/2020 Date
247.72(c) 243.19(c) 247.5(c) 242.59(c) 239.678 Last
6 042 471 2 745 529 2 172 592 2 104 482 166 949 Volume
-0.15% -1.83% +1.77% -1.98% -1.20% Change
More quotes
Financials
Sales 2020 25 395 M - 19 968 M
Net income 2020 6 888 M - 5 416 M
Net Debt 2020 19 337 M - 15 204 M
P/E ratio 2020 21,7x
Yield 2020 2,56%
Sales 2021 26 541 M - 20 869 M
Net income 2021 8 088 M - 6 360 M
Net Debt 2021 18 261 M - 14 358 M
P/E ratio 2021 18,2x
Yield 2021 2,73%
Capitalization 145 B 145 B 114 B
EV / Sales 2020 6,47x
EV / Sales 2021 6,15x
Nbr of Employees 23 400
Free-Float 99,8%
More Financials
Company
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc. The United States account for 74.5% of net sales; - other (5%): primarily royalties. 
More about the company
Notations Surperformance© of Amgen Inc.
Trading Rating : Investor Rating :
More Ratings
All news about AMGEN INC.
09/21AMGEN : AMG 160 at ESMO 2020 Presentation
PU
09/20AMGEN : Sotorasib at ESMO 2020
PU
09/20AMGEN : Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Publ..
PR
09/20MIRATI THERAPEUTICS : Amgen drug shrinks tumors in lung cancer patients with KRA..
RE
09/20Amgen says sotorasib shrank tumors in 32% of advanced lung cancer patients in..
RE
09/20Amgen says sotorasib study demonstrates progression-free survival of 6.3 mont..
RE
09/18AMGEN : Form 8937
PU
09/18AMGEN : For People With Lung Cancer, Expanded Biomarker Testing Is Key to Advanc..
PU
09/18ELI LILLY AND : Lilly and Amgen Announce Manufacturing Collaboration for COVID-1..
AQ
09/17ELI LILLY AND : Lilly, Amgen to Collaborate on Making Lilly's Potential Covid-19..
DJ
09/17AMGEN : Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibo..
PR
09/16AMGEN : To Webcast Investor Calls At ESMO 2020
PR
09/16AMGEN : To Showcase Data From Oncology Pipeline During ESMO Virtual Congress 202..
PR
09/16AMGEN : and MBC BioLabs Announce Winners of the Amgen Golden Ticket
AQ
09/15AMGEN : to Present at the 2020 Bank of America Virtual Global Healthcare Confere..
AQ
More news
News in other languages on AMGEN INC.
09/17Wall Street : en repli après de piètres statistiques
09/17AMGEN : collaboration avec Eli Lilly dans la Covid-19
09/17Wall Street : vers une ouverture déprimée après des données
09/17ELI LILLY : collaboration avec Amgen dans la Covid-19
09/04Vifor-Partner Akebia stellt trotz Studien-Fehlschlag Vadadustat-Zulassungsant..
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 260,65 $
Last Close Price 247,50 $
Spread / Highest target 24,4%
Spread / Average Target 5,31%
Spread / Lowest Target -25,3%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman, President & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
Peter H. Griffith Chief Financial Officer
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.2.67%144 959
JOHNSON & JOHNSON-1.14%379 679
ROCHE HOLDING AG8.39%315 948
MERCK & CO., INC.-8.81%209 775
PFIZER, INC.-8.07%201 437
NOVARTIS AG-11.13%195 696